Saturday 17 October 2026
Export ARAV’s income statement to Excel — free account
ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | |
|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
201.15 | 81.15 | 56.99 | 65.13 | 60.54 | 59.42 | 53.69 |
Total current assets |
205.31 | 81.71 | 58.03 | 68.21 | 61.69 | 62.75 | 57.97 |
Property, Plant, Equpment (Net) |
0.27 | 0.80 | 0.03 | 1.81 | 0.53 | 0.40 | 0.27 |
Long-term assets (Other) |
— | 2.38 | 2.42 | 3.18 | 2.44 | 2.44 | 2.45 |
Total non-current assets |
0.27 | 12.07 | 11.44 | 13.91 | 6.02 | 5.04 | 4.18 |
Total Assets |
205.57 | 93.78 | 69.47 | 82.12 | 67.71 | 67.79 | 62.15 |
Accounts Payable |
1.36 | 1.50 | 0.43 | 1.08 | 2.50 | 2.66 | 8.77 |
Accrued Expenses |
12.90 | 4.09 | 1.37 | 1.50 | 2.32 | 8.42 | 6.74 |
Current Part of Taxes to Pay |
0.25 | — | — | — | — | — | — |
Current Revenue (Deferred) |
— | — | 0.15 | 0.00 | 2.55 | 4.57 | 4.41 |
Other current liabilities |
40.00 | — | — | — | — | — | — |
Total current liabilities |
54.50 | 5.59 | 1.94 | 4.97 | 9.46 | 17.94 | 22.11 |
Long Term Debt (Total) |
— | 5.43 | 7.32 | — | — | — | — |
Non-current Revenue (Deferred) |
— | — | — | — | 3.76 | 3.55 | 0.62 |
Non-current Liabilities (Other) |
— | 5.43 | 0.26 | 0.26 | 3.76 | — | 26.88 |
Total non-current liabilities |
— | 5.43 | 7.59 | 8.10 | 10.19 | 7.62 | 29.38 |
Total liabilities |
54.50 | 11.02 | 9.53 | 13.07 | 19.66 | 25.57 | 51.50 |
Additional Paid In Capital |
440.67 | 456.99 | 510.51 | 539.16 | 548.71 | 582.03 | 626.78 |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Retained Earnings |
(289.25) | (374.23) | (450.56) | (470.11) | (500.65) | (539.80) | (616.13) |
Common Equity (Total) |
151.07 | 82.76 | 59.95 | 69.05 | 48.06 | 42.22 | 10.66 |
Shareholders Equity (Total) |
151.07 | 82.76 | 59.95 | 69.05 | 48.06 | 42.22 | 10.66 |
Shareholders Equity and Liabilities (Total) |
205.57 | 93.78 | 69.47 | 82.12 | 67.71 | 67.79 | 62.15 |
Shares (Common) |
5.81 | 5.99 | 11.27 | 15.00 | 16.48 | 21.04 | 59.85 |
Shareholders Equity (Tangible) |
151.07 | 82.76 | 59.95 | 69.05 | 48.06 | 42.22 | 10.66 |
Net Debt |
(201.15) | (75.72) | (49.67) | (65.13) | (60.54) | (59.42) | (53.69) |
Total Debt |
— | 5.43 | 7.32 | 7.84 | 6.43 | 4.08 | 1.88 |
In millions of $ except per-share values · columns are period end dates